Arm lymphoedema after axillary surgery in women with invasive breast cancer

British Journal of Surgery

Volumn 101, Issue 4, 2014, Pages 390-397

  Sackey, H ^a   Magnuson, A ^b   Sandelin, K ^a   Liljegren, G ^b   Bergkvist, L ^d   Fulep Z ^b   Celebioglu, F ^c   Frisell, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c STOCKHOLM SÖDER HOSPITAL   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT CHEMOTHERAPY; ARM; ARTICLE; AXILLA; BREAST TUMOR; COMPARATIVE STUDY; EVALUATION STUDY; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPHEDEMA; MASTECTOMY; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROSPECTIVE STUDY; SEGMENTAL MASTECTOMY; SELF REPORT; SENTINEL LYMPH NODE BIOPSY;

ARM; AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHEDEMA; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; PROSPECTIVE STUDIES; SELF REPORT; SENTINEL LYMPH NODE BIOPSY;

EID: 84894036791     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9401     Document Type: Article

References (39)

1. Tsai RJ, Dennis LK, Lynch CF, Snetselaar LG, Zamba GK, Scott-Conner C,. The risk of developing arm lymphedema among breast cancer survivors: a meta-analysis of treatment factors. Ann Surg Oncol 2009; 16: 1959-1972.
2. Cheville AL, McGarvey CL, Petrek JA, Russo SA, Thiadens SR, Taylor ME,. The grading of lymphedema in oncology clinical trials. Semin Radiat Oncol 2003; 13: 214-225. (Pubitemid 36962645)
3. Kuehn T, Klauss W, Darsow M, Regele S, Flock F, Maiterth C, et al,. Long-term morbidity following axillary dissection in breast cancer patients-clinical assessment, significance for life quality and the impact of demographic, oncologic and therapeutic factors. Breast Cancer Res Treat 2000; 64: 275-286. (Pubitemid 32055836)
4. Hack TF, Cohen L, Katz J, Robson LS, Goss P,. Physical and psychological morbidity after axillary lymph node dissection for breast cancer. J Clin Oncol 1999; 17: 143-149. (Pubitemid 29022387)
5. Montazeri A., Health-related quality of life in breast cancer patients: a bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res 2008; 27: 32.
6. Rief W, Bardwell WA, Dimsdale JE, Natarajan L, Flatt SW, Pierce JP,. Long-term course of pain in breast cancer survivors: a 4-year longitudinal study. Breast Cancer Res Treat 2011; 130: 579-586.
7. Kwan W, Jackson J, Weir LM, Dingee C, McGregor G, Olivotto IA,. Chronic arm morbidity after curative breast cancer treatment: prevalence and impact on quality of life. J Clin Oncol 2002; 20: 4242-4248. (Pubitemid 35191027)
8. Helms G, Kühn T, Moser L, Remmel E, Kreienberg R,. Shoulder-arm morbidity in patients with sentinel node biopsy and complete axillary dissection-data from a prospective randomised trial. Eur J Surg Oncol 2009; 35: 696-701.
9. Fleissig A, Fallowfield LJ, Langridge CI, Johnson L, Newcombe RG, Dixon JM, et al,. Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 2006; 95: 279-293.
10. Norman SA, Localio AR, Potashnik SL, Simoes Torpey HA, Kallan MJ, Weber AL, et al,. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol 2009; 27: 390-397.
11. Liljegren G, Holmberg L,. Arm morbidity after sector resection and axillary dissection with or without postoperative radiotherapy in breast cancer stage I. Results from a randomised trial. Uppsala-Orebro Breast Cancer Study Group. Eur J Cancer 1997; 33: 193-199.
12. McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, et al,. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 2008; 26: 5213-5219.
13. Petrek JA, Senie RT, Peters M, Rosen PP,. Lymphedema in a cohort of breast carcinoma survivors 20 years after diagnosis. Cancer 2001; 92: 1368-1377. (Pubitemid 32947819)
14. Petrek JA, Heelan MC,. Incidence of breast carcinoma-related lymphedema. Cancer 1998; 83 (Suppl): 2776-2781. (Pubitemid 29024266)
15. Bergkvist L, Frisell J,; Swedish Breast Cancer Group; Swedish Society of Breast Surgeons. Multicentre validation study of sentinel node biopsy for staging in breast cancer. Br J Surg 2005; 92: 1221-1224. (Pubitemid 41475230)
16. Bergkvist L, Frisell J, Liljegren G, Celebioglu F, Damm S, Thörn M,. Multicentre study of detection and false-negative rates in sentinel node biopsy for breast cancer. Br J Surg 2001; 88: 1644-1648. (Pubitemid 33124244)
17. Disipio T, Rye S, Newman B, Hayes S,. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol 2013; 14: 500-515.
18. Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, et al,. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006; 13: 491-500.
19. Rietman JS, Dijkstra PU, Geertzen JH, Baas P, de Vries J, Dolsma WV, et al,. Treatment-related upper limb morbidity 1 year after sentinel lymph node biopsy or axillary lymph node dissection for stage I or II breast cancer. Ann Surg Oncol 2004; 11: 1018-1024. (Pubitemid 40486669)
20. Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al.; National Surgical Adjuvant Breast, Bowel Project. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010; 102: 111-118.
21. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al,. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006; 98: 599-609. (Pubitemid 43904843)
22. Leidenius M, Leivonen M, Vironen J, von Smitten K,. The consequences of long-time arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance. J Surg Oncol 2005; 92: 23-31. (Pubitemid 41416425)
23. Langer I, Guller U, Berclaz G, Koechli OR, Schaer G, Fehr MK, et al,. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg 2007; 245: 452-461. (Pubitemid 46673142)
24. Del Bianco P, Zavagno G, Burelli P, Scalco G, Barutta L, Carraro P, et al,.; GIVOM. Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol 2008; 34: 508-513. (Pubitemid 351514885)
25. Husted Madsen A, Haugaard K, Soerensen J, Bokmand S, Friis E, Holtveg H, et al,. Arm morbidity following sentinel lymph node biopsy or axillary lymph node dissection: a study from the Danish Breast Cancer Cooperative Group. Breast 2008; 17: 138-147. (Pubitemid 351478254)
26. Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al,. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005; 23: 4312-4321. (Pubitemid 46209968)
27. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, et al,. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. New Engl J Med 2003; 349: 546-553. (Pubitemid 36951366)
28. Crane-Okada R, Wascher RA, Elashoff D, Giuliano AE,. Long-term morbidity of sentinel node biopsy versus complete axillary dissection for unilateral breast cancer. Ann Surg Oncol 2008; 15: 1996-2005.
29. Goldberg JI, Riedel ER, Morrow M, Van Zee KJ,. Morbidity of sentinel node biopsy: relationship between number of excised lymph nodes and patient perceptions of lymphedema. Ann Surg Oncol 2011; 18: 2866-2872.
30. Andersson Y, de Boniface J, Jonsson PE, Ingvar C, Liljegren G, Bergkvist L, et al,.; Swedish Breast Cancer Group; Swedish Society of Breast Surgeons. Axillary recurrence rate 5 years after negative sentinel node biopsy for breast cancer. Br J Surg 2012; 99: 226-231.
31. Swedish Breast Cancer Group. [National Guidelines for Treatment of Breast Cancer.] http://www.swebcg.se/Files/Docs/20130501-Nationella-riktlinjer130501. pdf [accessed 26 November 2013].
32. Giuliano AE, Kirgan DM, Guenther JM, Morton DL,. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220: 391-398.
33. Swedborg I., Voluminometric estimation of the degree of lymphedema and its therapy by pneumatic compression. Scand J Rehabil Med 1977; 9: 131-135. (Pubitemid 8318830)
34. Witte MH, Witte CL, Bernas M,. ISL Consensus Document revisited: suggested modifications (summarized from discussions at the 16th ICL, Madrid, Spain, September 1997 and the Interim ISL Executive Committee meeting). Lymphology 1998; 31: 138-140.
35. Gerber LH,. A review of measures of lymphedema. Cancer 1998; 83 (Suppl): 2803-2804. (Pubitemid 29024270)
36. Bourgeois P, Leduc O, Leduc A,. Imaging techniques in the management and prevention of posttherapeutic upper limb edemas. Cancer 1998; 83 (Suppl): 2805-2813. (Pubitemid 29024271)
37. Megens AM, Harris SR, Kim-Sing C, McKenzie DC,. Measurement of upper extremity volume in women after axillary dissection for breast cancer. Arch Phys Med Rehabil 2001; 82: 1639-1644. (Pubitemid 33126666)
38. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al.; International Breast Cancer Study Group Trial 23-01 investigators. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013; 14: 297-305.
39. Shah-Khan M, Boughey JC,. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial. Cancer Control 2012; 19: 267-276.